Business Wire

MITSUI-CHEMICALS

Share
Mitsui Chemicals Group to Exhibit at K2022 Trade Fair in Düsseldorf, Germany

Mitsui Chemicals, Inc. (Tokyo: 4183; President & CEO: HASHIMOTO Osamu) and Mitsui Chemicals Europe GmbH (Düsseldorf, Germany; President: HIRAIWA Takeshi) will exhibit at K2022 – the World’s No.1 Trade Fair for Plastics and Rubber as the Mitsui Chemicals Group.
The event is scheduled to be held from October 19–26, 2022 in Düsseldorf, Germany.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221005005348/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Mitsui Chemicals Group booth (Graphic: Business Wire)

At the trade fair, under the slogan “Feel Good Chemistry for a sustainable world”, the Mitsui Chemicals Group will present innovative materials and solutions that contribute to the circular economy, and a carbon neutral and sustainable society. In addition, technical presentations will be held on October 20th and 24th.
Come and meet us at our booth at K 2022 (hall 7a, booth D18).

  • Overview of Mitsui Chemicals Group‘s Exhibition

Exhibition period:

October 19 (Wed) – October 26 (Wed), 2022

Venue:

Düsseldorf Fairgrounds / Düsseldorf, Germany

Booth location:

7a / D18

  • Exhibition items of Materials and information

Products/Solutions

Theme

Arlen™

A modified polyamide 6T, heat & hydrolysis resistance for metal replacements and EV components

Aurum™

(TPI), a super engineering plastic for high performance applications at extreme temperatures

Arcus™

Solution service for polymer robot parts including material design/selection and production.

Exfola™

Sealant film for packaging with good oil and water repellency

Econykol™

Biomass based polyols for polyurethanes that contributes to reduce greenhouse gas emissions

Recycle solutions
for packaging

RePLAYERTM – Renewable plastic layer system -

Mono-material packaging solutions

Paper packaging solutions

TAFNEX™

Composite material based on polypropylene and carbon fibre for structural and aesthetic applications

TPXTM

Polymethylpentene (PMP), a polyolefin based polymer with extremely low density, high melting point, releasability and steam resistance for autoclavable medical and laboratory equipment

Advanced Module Concept

Advanced module concept for back-door and slide-door

Eco-bench

MMP (Mold Master Plate) - sandwich molding (Recycling)

  • Technical presentations

- October 20, 11:00 o’clock
Theme: "AURUMTM thermoplastic polyimide (TPI)
An innovative solution for the demanding application requirements by maintaining excellent mechanical performance at extreme temperatures"
Presenter: Samer Ziadeh
Technical Expert, Product Support Team, R&D Division

- October 24, 14:00 o’clock
Theme: "Decorative design options with thermoplastic composites based on carbon fiber and polypropylene"
Presenter: Dr. Christos Karatzias
Senior Manager, New Business Development Team, R&D Division

Please visit our dedicated website for more details.
https://eu.mitsuichemicals.com/special/k2022/

About Mitsui Chemicals (Tokyo: 4183, ISIN: JP3888300005)
Mitsui Chemicals’ roots can be traced back to 1912 when it began producing raw material for chemical fertilizers from coal gas byproducts, the first company in Japan to do so. This undertaking significantly contributed to increasing agricultural productivity, a major social issue at the time. Later, the company evolved its technology from coal chemicals to gas chemicals, and in 1958 it built Japan’s first petrochemical complex and so provided impetus to Japan’s industry. Today, the company boasts many world-class products with sales standing at over 1,600 billion yen and with over 160 companies in 30 countries. Its business portfolio includes Life & Healthcare Solutions, Mobility Solutions, ICT Solutions, Basic & Green Materials.
Mitsui Chemicals will continue to contribute to solving social challenges with its state-of-the-art technology and by "Creating New Customer Value through Innovation".
More information can be found at https://www.mitsuichem.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005348/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enginzyme and AGC Create Scalable Process for Key mRNA Ingredient12.1.2026 06:00:00 CET | Press release

At the mRNA Health conference in Berlin, enginzyme and AGC Inc. presented a scalable process to produce a key mRNA vaccine and therapy ingredient, N1-methylpseudouridine-5'-triphosphate (m¹ΨTP). The rapid growth of mRNA-based vaccines and therapeutics has driven significant demand for modified nucleotides like m¹ΨTP, which enhances mRNA stability and expression, while reducing immunogenicity. Enginzyme is a deep-tech company delivering optimized biomanufacturing solutions through cell-free enzyme engineering technology. AGC Inc. is a leading global player in fields spanning from architectural glass to chemicals and life science. AGC Inc. provides services in a wide range of life science fields, from synthetic pharmaceuticals and agrochemicals, to biopharmaceuticals and leading-edge cell and gene therapies, as well as messenger RNAs. The presentation in November detailed the latest collaboration between the companies, with a focus on the biomanufacturing of nucleotides for mRNA therapy,

Ant International Partners with Google’s Universal Commerce Protocol to Expand AI Capabilities12.1.2026 02:15:00 CET | Press release

Ant International, a leading global payment, digitisation, and financial technology provider, is collaborating on the launch of Google’s Universal Commerce Protocol (UCP), a new open standard for agentic commerce that works across the entire shopping journey — from discovery and buying to post-purchase support. UCP establishes a common language for agents and systems to operate together across consumer surfaces, businesses, and payment providers to enable commerce. So instead of requiring unique connections for every individual agent, UCP enables all agents to interact easily. UCP is built to work across verticals and is compatible with existing industry protocols like Agent2Agent (A2A), Agent Payments Protocol (AP2), and Model Context Protocol (MCP). “For agentic commerce to scale, it’s critical for the industry to align on a common set of standards. We are proud to have Ant International endorse the Universal Commerce Protocol as the foundation for that future,” said Ashish Gupta, VP

Torq Secures $140M Series D at $1.2B Valuation to Lead the AI SOC and Agentic AI Era11.1.2026 17:59:00 CET | Press release

Fueled by Massive Customer Adoption of AI Agents, Torq Scales the World’s First True AI SOC Platform and Accelerates Expansion into the U.S. Federal Market Torq, the established Agentic AI security operations pioneer, today announced it has closed a massive $140 million Series D funding round, propelling its valuation to $1.2 billion and total funding to $332M. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260112510774/en/ Led by Merlin Ventures—a leading cybersecurity fund renowned for its deep access to the U.S. commercial and Public Sector markets—with participation from all existing investors, including Evolution Equity Partners, Notable Capital, Bessemer Venture Partners, Insight Ventures Partners, and Greenfield Partners, this capital injection is a definitive investment in the future of security. Torq is driving the industry’s critical shift: the complete transformation of the Security Operations Center (SOC) through

Andersen udvider sine kompetencer med tilføjelsen af Scimitar9.1.2026 21:44:00 CET | Pressemeddelelse

Andersen Consulting har indgået en samarbejdsaftale med Scimitar, der er et firma med fokus på at accelerere innovation i biovidenskabsbranchen. Scimitar, der har hovedkvarter i USA, et førende konsulenthus inden for strategieksekvering for biovidenskabsbranchen. Virksomheden er specialiseret i design af driftsmodeller, digital transformation og organisatorisk forandring. Scimitar samarbejder med medicinal- og biotech-virksomheder om at accelerere innovation, styrke den driftsmæssige eksekvering og sikre compliance gennem hele produkters livscyklus. Deres praktiske og samarbejdsorienterede tilgang sikrer løsninger, der ikke blot er formålstjenlige, men også skalerbare. "Virksomheder inden for biovidenskabsbranchen befinder sig i en tid med hurtige videnskabelige fremskridt, stigende regulatorisk kompleksitet og et voksende behov for operationel agilitet, samtidig med at de holdes op mod de højeste standarder for patientsikkerhed og dataintegritet," udtaler Ramy Khalil, CEO i Scimitar.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye